Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:GOSS NASDAQ:MOR NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$39.08+4.1%$29.26$14.80▼$40.47$2.98B0.87992,231 shs670,933 shsGOSSGossamer Bio$2.82+4.4%$2.39$0.66▼$3.60$641.21M1.952.33 million shs2.68 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARAREUltragenyx Pharmaceutical$30.36+4.4%$29.09$25.81▼$57.99$2.93B0.211.35 million shs2.40 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology0.00%+1.73%+39.97%+44.38%-0.87%GOSSGossamer Bio0.00%-11.48%+9.31%+119.51%+181.25%MORMorphoSys0.00%0.00%0.00%0.00%0.00%RAREUltragenyx Pharmaceutical0.00%+3.38%-2.94%-20.02%-46.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$39.08+4.1%$29.26$14.80▼$40.47$2.98B0.87992,231 shs670,933 shsGOSSGossamer Bio$2.82+4.4%$2.39$0.66▼$3.60$641.21M1.952.33 million shs2.68 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARAREUltragenyx Pharmaceutical$30.36+4.4%$29.09$25.81▼$57.99$2.93B0.211.35 million shs2.40 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology0.00%+1.73%+39.97%+44.38%-0.87%GOSSGossamer Bio0.00%-11.48%+9.31%+119.51%+181.25%MORMorphoSys0.00%0.00%0.00%0.00%0.00%RAREUltragenyx Pharmaceutical0.00%+3.38%-2.94%-20.02%-46.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.92Moderate Buy$56.5546.81% UpsideGOSSGossamer Bio 3.00Buy$8.50214.23% UpsideMORMorphoSys 0.00N/AN/AN/ARAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50166.38% UpsideCurrent Analyst Ratings BreakdownLatest GOSS, MOR, RARE, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/26/2025CGONCG OncologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$41.00 ➝ $47.009/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$56.00 ➝ $79.009/15/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/11/2025GOSSGossamer BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/8/2025CGONCG OncologyJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.009/8/2025CGONCG OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$75.009/5/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.009/1/2025CGONCG OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/18/2025CGONCG OncologyPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$55.00(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$1.14M2,576.18N/AN/A$9.63 per share4.00GOSSGossamer Bio$114.70M5.36N/AN/A$0.13 per share20.81MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17RAREUltragenyx Pharmaceutical$560.23M5.26N/AN/A$2.76 per share11.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ARAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)Latest GOSS, MOR, RARE, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025CGONCG Oncology-$0.49-$0.54-$0.05-$0.54$0.11 millionN/A8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 million8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A22.1522.15GOSSGossamer Bio6.704.404.40MORMorphoSys4.981.381.38RAREUltragenyx PharmaceuticalN/A2.452.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%GOSSGossamer Bio81.23%MORMorphoSys18.38%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipCGONCG OncologyN/AGOSSGossamer Bio6.70%MORMorphoSys0.05%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6176.25 millionN/AOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableGOSS, MOR, RARE, and CGON HeadlinesRecent News About These CompaniesRegeneron nabs FDA label expansion for Ultragenyx-partnered cholesterol drugSeptember 26 at 7:20 PM | msn.comUltragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 24, 2025 | seekingalpha.comAssenagon Asset Management S.A. Has $42.31 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 22, 2025 | marketbeat.comVoya Investment Management LLC Sells 9,125 Shares of Ultragenyx Pharmaceutical Inc. $RARESeptember 22, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Grants Restricted Stock Units to New Non-Executive OfficersSeptember 19, 2025 | quiverquant.comQUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 19, 2025 | globenewswire.comRep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) SharesSeptember 17, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 17, 2025 | marketbeat.comIs Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?September 16, 2025 | insidermonkey.comGreat Lakes Advisors LLC Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 15, 2025 | marketbeat.comMillennium Management LLC Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 14, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 2,450 SharesSeptember 13, 2025 | insidertrades.comHC Wainwright Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)September 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLCSeptember 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comCantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)September 9, 2025 | theglobeandmail.comUltragenyx Reports Positive Phase 3 Gene Therapy ResultsSeptember 9, 2025 | msn.comRARE Reports Positive Long-Term Data From Metabolic Disorder StudySeptember 9, 2025 | zacks.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Alliancebernstein L.P.September 9, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Reports Positive Phase 3 Results for DTX401 Gene Therapy in Glycogen Storage Disease Type Ia with Significant Reductions in Cornstarch Intake and Improved Glycemic ControlSeptember 8, 2025 | quiverquant.comQUltragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)September 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025After the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock LowerBy Gabriel Osorio-Mazilli | September 2, 2025GOSS, MOR, RARE, and CGON Company DescriptionsCG Oncology NASDAQ:CGON$39.08 +1.54 (+4.10%) Closing price 04:00 PM EasternExtended Trading$37.39 -1.69 (-4.33%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Gossamer Bio NASDAQ:GOSS$2.82 +0.12 (+4.44%) Closing price 04:00 PM EasternExtended Trading$2.78 -0.04 (-1.56%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 09/26/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Ultragenyx Pharmaceutical NASDAQ:RARE$30.36 +1.28 (+4.40%) Closing price 04:00 PM EasternExtended Trading$30.79 +0.43 (+1.42%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin ASML Is a Hidden Gem in This Technology Rally, a Catch Up Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
